Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) FCF Margin: 2024-2025

Historic FCF Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to 781.46%.

  • Monte Rosa Therapeutics' FCF Margin rose 101359.00% to 781.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.89%, marking a year-over-year change of. This contributed to the annual value of 50.26% for FY2024, which is N/A change from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' FCF Margin stood at 781.46%, which was up 597.74% from -157.00% recorded in Q2 2025.
  • Monte Rosa Therapeutics' FCF Margin's 5-year high stood at 781.46% during Q3 2025, with a 5-year trough of -3,717.01% in Q1 2024.
  • Over the past 2 years, Monte Rosa Therapeutics' median FCF Margin value was -157.00% (recorded in 2025), while the average stood at -543.19%.
  • Data for Monte Rosa Therapeutics' FCF Margin shows a peak YoY skyrocketed of 366,158bps (in 2025) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' FCF Margin (Quarterly) stood at 212.28% in 2024, then spiked by 101,359bps to 781.46% in 2025.
  • Its last three reported values are 781.46% in Q3 2025, -157.00% for Q2 2025, and -55.43% during Q1 2025.